Business Wire (Thu, 8:00AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,319 people get NPSP articles and Market Currents by email alert.
Get email alerts on NPSP »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
-
-
-
-
-
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 21, 2013)
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
Current Prime Pharma Entries In Anticipation Of Prime Time ExitsChemistfrog • Tue, Nov 6, 2012 -
-
What Moves Biotech Stocks? Ed Arce Has AnswersLife Sciences Report • Thu, Oct 18, 2012 -
-
-
-
-
-
NPS Pharmaceuticals' CEO Discusses Gattex Update (Transcript)Wed, Oct 17, 2012 • 1 Comment
-
NPS Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptThu, May 6, 2010
-
NPS Pharmaceuticals Inc. Q4 2008 Earnings Call TranscriptFri, Mar 13, 2009
-
NPS Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptTue, Sep 2, 2008
-
Business Wire (May 9, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 26, 2013)
-
Business Wire (Apr 22, 2013)
-
Business Wire (Mar 5, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 19, 2013)
-
Business Wire (Feb 13, 2013)
-
Business Wire (Feb 5, 2013)
-
at CNBC.com (Jan 7, 2013)
-
Business Wire (Jan 3, 2013)
-
Business Wire (Dec 21, 2012)
NPSP vs. ETF Alternatives
Company Description
Currently, there's no company description for NPSP.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Thursday, May 9, 1:52 PM NPS Pharmaceuticals (NPSP +5.2%) moves up today after its Q1 bottom line comes in better than Street estimates. Net losses on a per share basis were 25% lower than the prior year on higher royalty revenue and the company begins to see its rollout of Gattex take hold. It comfirms financial guidance for 2013, and says it continues to expect its operating expenses to be between $135M and $145M. Comment! [Healthcare, Earnings]
- Thursday, May 9, 8:04 AM NPS Pharmaceuticals (NPSP): Q1 EPS of -$0.09 beats by $0.04. Revenue of $25.4M misses by $2.16M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, May 9, 12:05 AM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
- Wednesday, May 8, 5:30 PM Notable earnings before Thursday’s open: AES, AGU, ALR, AM, AMRC, APA, BAM, BCE, CBB, CNSL, CTB, CVC, DF, DISH, DNDN, GLP, GTIV, IRC, KEM, KIOR, MEA, NPSP, OWW, PCP, SNE, SNSS, SPH, SRPT, TK, TNK, VICL, VNDA, WAC, WFR, WIN, WWAV, XRAY Comment! [Earnings]
- Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
- Wednesday, April 24, 9:24 AM Oppenheimer initiates NPS Pharmaceuticals (NPSP) at Outperform with a price target of $18. "There are no direct competitors for Gattex and Natpara," writes analyst Boris Peaker, adding that investors shouldn't be wary of "owning a launch name" in this case because the company's "first-in-class compounds [should] generate substantial commercial traction given their therapeutic benefits." Shares +1.81% premarket. Comment! [On the Move, Healthcare]
-
Tuesday, March 19, 1:00 PM
Midday top 10 gainers: EFUT +53%. ATOS +29%. GST +20%. KYTH +14%. DWCH +10%. NPSP +9%. SHIP +9%. CSTE +8%. OPXA +8%. LTRX +8%.
Midday top 10 losers: AFFY -64%. MTSL -33%. HNR -33%. WSCI -23%. WAC -19%. INTX -19%. STSI -17%. TWER -14%. CLWT -13%. GMXR -13%. Comment! [On the Move] -
Tuesday, March 19, 9:10 AM
Premarket gainers: NPSP +10%. SKUL +7%. ABC +6%. ACAD +5%.
Losers: AFFY -59%. HNR -46%. MTSL -30%. STSI -11%. CAH -8%. DSW -7%. HPT -6%. Comment! [On the Move] - Tuesday, March 19, 8:18 AM NPS Pharmaceuticals (NPSP) has bought back the none-North American rights to two drugs from Takeda for $50M in shares and possible milestone payments, giving NPS with full global rights to the treatments. The drugs are Revestive (Gattex in the U.S.), a medicine for short bowel syndrome, and Preotact, a thyroid hormone replacement therapy. (PR) Comment! [Healthcare, M&A]
- Thursday, February 21, 4:25 PM NPS Pharmaceuticals (NPSP): Q4 EPS of -$0.14 misses by $0.05. Revenue of $27.2M misses by $1.73M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, February 21, 12:10 AM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD Comment! [Earnings]
- Wednesday, February 20, 5:35 PM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD 2 Comments [Earnings]
- Wednesday, February 13, 12:10 AM Notable earnings after Wednesday’s close: AEM, AMAT, ANGI, CAR, CJES, CLD, CSCO, CTL, CXW, ENOC, EOG, EQIX, IO, IPI, ITRI, KGC, MDLZ, MET, NPSP, NTAP, NVDA, OII, PSE, PXD, ROVI, SKX, SMSI, TAL, TNGO, TRGT, TRIP, VCLK, WFM, WRE, WTW, Z Comment! [Earnings]
- Tuesday, February 12, 5:35 PM Notable earnings after Wednesday’s close: AEM, AMAT, ANGI, CAR, CJES, CLD, CSCO, CTL, CXW, ENOC, EOG, EQIX, IO, IPI, ITRI, KGC, MDLZ, MET, NPSP, NTAP, NVDA, OII, PSE, PXD, ROVI, SKX, SMSI, TAL, TNGO, TRGT, TRIP, VCLK, WFM, WRE, WTW, Z 2 Comments [Earnings]
- Friday, December 21, 2012, 4:04 PM NPS Pharmaceuticals (NPSP +04%) says the FDA has approved Gattex for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support. The company says Gattex will be available in Q113. Comment! [Healthcare]
- Friday, November 9, 2012, 8:07 AM NPS Pharmaceuticals (NPSP): Q3 EPS of -$0.04 beats by $0.12. Revenue of $27M (+9.8% Y/Y) misses by $1.2M. (PR) Comment! [Earnings, Healthcare]
-
Codespeed
$NBIX $NPSP technical charts, strong catalysts, good returns: http://seekingalpha.com/a/syx1 - View all 0 replies
-
- View all 1 replies
-
-
- View all 1 replies
-
whitehead1: I missed and missed and missed. Please go under 5 for one more time please
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
- View all 0 replies
-
Corey Papcun
NPSP was scheduled to report 3rd quarter earnings today at 4:30. Are they holding off due to the election? - View all 1 replies
-
-
freefdawatchlist
http://stks.co/mCem Premarket loser $FTNT (-16%), $APOL (-12%), $ISRG (-5%), $NPSP (-4%), $INTC(-4%) - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
"FDA staff says NPS Pharma's (NPSP) bowel drug needs no safety restrictions." Drug may be nearing approval. http://bit.ly/SWHPDY - View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 1 replies
-
whitehead1: I missed and missed and missed. Please go under 5 for one more time please
-
smokeyRose
Should i sell Should i sell My $JAZZ and $NPSP and Buy $SRPT ????? What to do What To Do What To Do - View all 2 replies
-
-
-
Corey Papcun
NPSP was scheduled to report 3rd quarter earnings today at 4:30. Are they holding off due to the election? - View all 1 replies
-
-
- View all 1 replies
-